Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Pelvic mesh class actions settle for $300m

Two class actions against Johnson & Johnson over defective pelvic mesh products have settled for $300 million, finalising almost 10 years of legal fighting.

AAP

Johnson & Johnson reaches $300m settlement over pelvic mesh implants

Settlement of two Australian class actions is largest in country’s history and subject to federal court approval

The Guardian - AU

Johnson & Johnson Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

This Is What Whales Are Betting On Johnson & Johnson

Someone with a lot of money to spend has taken a bullish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Johnson & Johnson Whale Trades For August 23

Benzinga

Pharma funds Illinois pols, ‘Sister Jean’ turns 103, Honest Chicagoans talk Air and Water Show and more in your Chicago news roundup

Today’s update is a 5-minute read that will brief you on the day’s biggest stories.

Chicago Sun-Times

Illinois Senate President Don Harmon, other pols keep taking money from pharma companies implicated in opioid crisis

The Oak Park Democrat continues to accept campaign money from Johnson & Johnson, 1 of 4 companies paying $26 billion to settle suits accusing them of fueling the crisis. He’s not the only Illinois official doing so.

Chicago Sun-Times

Read news from The Economist, FT, and more,
with one subscription

If You Invested $1,000 In Johnson & Johnson Stock At Its COVID-19 Pandemic Low, Here's How Much You'd Have Now

Investors who bought stocks during the COVID-19 market crash in 2020 have generally experienced some big gains in the past two years. But there is no question some big-name stocks performed better than others since the pandemic bottom.

Benzinga

Johnson & Johnson baby powder to be removed from all UK stores in 2023

The company cites commercial reasons and has blamed 'misinformation' over the safety of the product for its declining sales in the past.

Daily Record

More than a half billion doses of COVID vaccine made in Baltimore dumped, congressional panel finds

BALTIMORE — The tally of wasted COVID-19 vaccine continues to climb at the troubled Emergent BioSolutions plant in East Baltimore and now exceeds a half billion doses, according to findings a congressional panel released Thursday on the manufacturer once central to the U.S. coronavirus pandemic response.

Tribune News Service

Walgreens fueled San Francisco's opioid crisis with thousands of 'suspicious orders,' judge rules

Walgreens helped fuel the opioid epidemic in San Francisco by shipping hundreds of thousands of "suspicious orders" of prescription drugs to its pharmacies, a federal judge ruled Wednesday.

Los Angeles Times

Johnson & Johnson Whale Trades Spotted

Benzinga

New book chronicles how America's opioid industry operated like a drug cartel

Two Washington Post journalists say pharmaceutical companies collaborated with each other — and with lawyers and lobbyists — to create laws to protect the industry. Their new book is American Cartel.

WEKU

Johnson & Johnson Whale Trades For July 25

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Things Looking Up at Johnson & Johnson?

Johnson & Johnson (NYSE: JNJ) released their financial report for the second quarter of 2022, this week, demonstrating strong growth and promising guidance for the rest of the year. Analysts seem to agree, as the consensus rating for JNJ is MODERATE BUY.

Benzinga

US Stock Futures Higher Ahead of J&J, Netflix Earnings

Pre-open movers

The Independent UK

Covid vaccine protection ‘short lived,’ booster doses essential, study confirms

‘Continual updating of our vaccinations and booster shots is critical,’ scientists say

Benzinga

Looking At Johnson & Johnson's Recent Whale Trades

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Looking At Johnson & Johnson's Recent Whale Trades

The Conversation

COVID vaccines and pregnancy: a review of the evidence shows they are safe

COVID vaccines have been contentious ever since they were developed in response to the coronavirus pandemic, though the evidence is that they are safe and effective. One of the concerns has been whether the vaccines were safe for pregnant women. A recent review looked at the evidence available from North…

Benzinga

Check Out What Whales Are Doing With JNJ

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 15 strange trades.

Tribune News Service

How a Texas town is making itself into an epicenter of the US semiconductor universe

In downtown Sherman, Texas, markers explain the city’s past and restaurants and coffee shops boast about the historic buildings they call home.

Benzinga

Here's How Much You Would Have Made Owning Johnson & Johnson Stock In The Last 15 Years

Johnson & Johnson (NYSE:JNJ) has outperformed the market over the past 15 years by 1.01% on an annualized basis producing an average annual return of 7.22%. Currently, Johnson & Johnson has a market capitalization of $465.27 billion.

Benzinga

What Are Whales Doing With Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 12 strange trades.

Benzinga

Here's How Much You Would Have Made Owning Johnson & Johnson Stock In The Last 15 Years

Johnson & Johnson (NYSE:JNJ) has outperformed the market over the past 15 years by 1.05% on an annualized basis producing an average annual return of 7.34%. Currently, Johnson & Johnson has a market capitalization of $469.49 billion.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.